Figure 1From: Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer Different parts of the treatment schedule. Patients received dose-dense sequential epirubicin and paclitaxel, followed by capecitabine alone (dose levels 1 and 3) or with vinorelbine (dose levels 2 and 4).Back to article page